An Open-label, Randomized, Controlled Trial to Evaluate the Efficacy of Sotatercept Add-on Therapy Compared to Standard PAH Therapy With Pulmonary Vasodilators for Pulmonary Arterial Hypertension Associated With Pulmonary Vasodilator-resistant, Unrepaired Congenital Shunts (ASD, VSD, PDA) Including Eisenmenger Syndrome SuMILE Trial
Latest Information Update: 02 Feb 2026
At a glance
- Drugs Sotatercept (Primary) ; Endothelin receptor antagonists; Epoprostenol; Riociguat; Type 5 cyclic nucleotide phosphodiesterase inhibitors
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms SuMILE
Most Recent Events
- 02 Feb 2026 New trial record